Stay updated with breaking news from Bdr Pharmaceuticals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
It is a more patient-friendly way to tackle prostate cancer. It can help improve patient compliance to a great extent, Badiger said. The company said introducing the Drug Controller General of India (DCGI)approved new drug delivery system will make it more affordable and accessible in India.
The performance in terms of stamp duty collection led by the heightened activity in premium and mid-income housing segments have also pushed the state exchequers revenue higher for several months. In the first 10 months of the current year, the state government has already fetched over Rs 9,220 crore through stamp duty collection surpassing the all-time high of over Rs 8,893 crore recorded in 2022.
Mumbai: The performance in terms of stamp duty collection led by the heightened activity in premium and mid-income housing segments have also pushed the state exchequer’s revenue higher for several months.
BDR Pharma partners with Varenyam Healthcare
BDR Pharmaceuticals on Monday said it has launched prostate cancer treatment drug Enzalutamide in 160 mg strength.The company has introduced the medication, under the brand name BDENZA 160mg, at Rs 6,300 for a strip of seven tablets.The medicine was previously available in 40 mg and 80 mg strength for which patients had to consume two tablets a day.